HUE036387T2 - Pirrolopirimidin származékok vírusfertõzések kezelésében való felhasználásra - Google Patents

Pirrolopirimidin származékok vírusfertõzések kezelésében való felhasználásra

Info

Publication number
HUE036387T2
HUE036387T2 HUE14198125A HUE14198125A HUE036387T2 HU E036387 T2 HUE036387 T2 HU E036387T2 HU E14198125 A HUE14198125 A HU E14198125A HU E14198125 A HUE14198125 A HU E14198125A HU E036387 T2 HUE036387 T2 HU E036387T2
Authority
HU
Hungary
Prior art keywords
treatment
viral infections
pyrrolopyrimidine derivatives
pyrrolopyrimidine
derivatives
Prior art date
Application number
HUE14198125A
Other languages
English (en)
Inventor
Shanta Bantia
Pravin L Kotian
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of HUE036387T2 publication Critical patent/HUE036387T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14198125A 2010-10-15 2011-10-14 Pirrolopirimidin származékok vírusfertõzések kezelésében való felhasználásra HUE036387T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39352210P 2010-10-15 2010-10-15
US201161492054P 2011-06-01 2011-06-01

Publications (1)

Publication Number Publication Date
HUE036387T2 true HUE036387T2 (hu) 2018-07-30

Family

ID=45938737

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14198125A HUE036387T2 (hu) 2010-10-15 2011-10-14 Pirrolopirimidin származékok vírusfertõzések kezelésében való felhasználásra

Country Status (24)

Country Link
US (6) US20130331404A1 (hu)
EP (3) EP2898885B1 (hu)
JP (2) JP5902698B2 (hu)
KR (1) KR101850925B1 (hu)
CN (1) CN103429245B (hu)
AU (2) AU2011315902B2 (hu)
BR (1) BR112013009029B1 (hu)
CA (1) CA2813783C (hu)
CY (1) CY1119880T1 (hu)
DK (2) DK2627334T3 (hu)
ES (2) ES2657687T3 (hu)
HK (2) HK1212914A1 (hu)
HR (2) HRP20150487T1 (hu)
HU (1) HUE036387T2 (hu)
IL (1) IL225672B (hu)
LT (1) LT2898885T (hu)
MX (1) MX348759B (hu)
PL (2) PL2898885T3 (hu)
PT (2) PT2898885T (hu)
RS (2) RS54072B1 (hu)
RU (3) RU2599013C2 (hu)
SI (2) SI2898885T1 (hu)
SM (1) SMT201500148B (hu)
WO (1) WO2012051570A1 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2937350T1 (en) 2008-04-23 2018-05-31 Gilead Sciences, Inc. 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
UA111163C2 (uk) 2010-07-22 2016-04-11 Гайлід Сайєнсіз, Інк. Способи й сполуки для лікування вірусних інфекцій paramyxoviridae
RU2599013C2 (ru) 2010-10-15 2016-10-10 БАЙОКРИСТ ФАРМАСЬЮТИКАЛЗ, ИНК. (э ЮЭс корпорейшн) Способы и композиции для ингибирования полимеразы
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
JP2016504284A (ja) * 2012-11-16 2016-02-12 バイオクリスト ファーマスーティカルズ,インコーポレイテッドBiocryst Pharmaceuticals,Inc. 抗ウイルス性アザ糖を含有するヌクレオシド
US9499554B2 (en) 2013-05-14 2016-11-22 Biocryst Pharmaceuticals, Inc. Anti-influenza compositions and methods
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CN104513249B (zh) * 2014-12-26 2016-08-31 苏州明锐医药科技有限公司 抗埃博拉病毒药物bcx4430的制备方法
LT3349758T (lt) 2015-09-16 2022-07-11 Gilead Sciences, Inc. Arenavirusų šeimos virusinių infekcijų gydymo būdai
US10512649B2 (en) 2016-03-06 2019-12-24 Biocryst Pharmaceuticals, Inc. Methods and compositions for treatment of zika virus infection
DE102016002873A1 (de) 2016-03-09 2016-05-25 Heinz Kiefer Zellnachweisverfahren und Screeningverfahren von Stoffbibliotheken zur Identifizierung von Einzelstoffen, die im Falle einer bioterroristischen Bedrohung gegen Mischungen synthetischer Viren wirksam sind
EP3595672B1 (en) 2017-03-14 2023-09-06 Gilead Sciences, Inc. Compounds for use in methods of treating feline coronavirus infections
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3651734A1 (en) 2017-07-11 2020-05-20 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
WO2021007283A1 (en) * 2019-07-09 2021-01-14 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
CN118662520A (zh) 2020-01-27 2024-09-20 吉利德科学公司 用于治疗SARS CoV-2感染的方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
WO2021207386A1 (en) * 2020-04-07 2021-10-14 Biocryst Pharmaceuticals, Inc. Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections
CN115666570A (zh) 2020-05-29 2023-01-31 吉利德科学公司 瑞德西韦治疗方法
AU2021296841A1 (en) 2020-06-24 2023-02-16 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
EP4424372A2 (en) 2020-08-27 2024-09-04 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
EP4360629A4 (en) * 2021-06-25 2024-11-06 Univ Nat Chonnam Ind Found PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR FOR THE TREATMENT OR MANAGEMENT OF RNA VIRUS INFECTIONS
US11963959B2 (en) 2021-08-17 2024-04-23 Southwest Research Institute Inhibitors for coronavirus
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9520364D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compouundds
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) * 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
WO2003100009A2 (en) * 2002-05-23 2003-12-04 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
WO2006002231A1 (en) 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US7514410B2 (en) * 2005-03-29 2009-04-07 Biocryst Pharmaceuticals, Inc. Hepatitis C therapies
US20090227637A1 (en) * 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
WO2008030119A1 (en) 2006-09-07 2008-03-13 Industrial Research Limited Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
WO2008067002A2 (en) 2006-09-11 2008-06-05 Southern Research Institute Azole nucleosides and use as inhibitors of rna and dna varial polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
RU2599013C2 (ru) 2010-10-15 2016-10-10 БАЙОКРИСТ ФАРМАСЬЮТИКАЛЗ, ИНК. (э ЮЭс корпорейшн) Способы и композиции для ингибирования полимеразы
BR112013009531A2 (pt) * 2010-11-11 2016-07-19 Redx Pharma Ltd derivados de fármaco
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral

Also Published As

Publication number Publication date
IL225672A0 (en) 2013-06-27
IL225672B (en) 2019-02-28
US20190374544A1 (en) 2019-12-12
SMT201500148B (it) 2015-09-07
US20130331404A1 (en) 2013-12-12
PT2898885T (pt) 2018-02-05
PT2627334E (pt) 2015-07-07
KR20140040676A (ko) 2014-04-03
PL2898885T3 (pl) 2018-04-30
RU2599013C2 (ru) 2016-10-10
US20180360836A1 (en) 2018-12-20
MX348759B (es) 2017-06-28
US20170042901A1 (en) 2017-02-16
HRP20150487T1 (hr) 2015-08-28
DK2627334T3 (en) 2015-05-18
WO2012051570A1 (en) 2012-04-19
LT2898885T (lt) 2018-02-26
BR112013009029B1 (pt) 2021-06-29
CN103429245A (zh) 2013-12-04
US10420769B2 (en) 2019-09-24
US10022375B2 (en) 2018-07-17
EP3345605A1 (en) 2018-07-11
JP2016135790A (ja) 2016-07-28
HK1212914A1 (zh) 2016-06-24
BR112013009029A2 (pt) 2018-06-19
CY1119880T1 (el) 2018-06-27
RU2718690C2 (ru) 2020-04-13
EP2898885A1 (en) 2015-07-29
EP2627334B1 (en) 2015-04-29
DK2898885T3 (en) 2018-02-05
AU2011315902B2 (en) 2016-11-17
RU2016134401A (ru) 2018-12-10
SI2627334T1 (sl) 2015-08-31
JP2013544788A (ja) 2013-12-19
EP2627334A4 (en) 2014-04-16
EP3345605B1 (en) 2019-11-20
US20220040190A1 (en) 2022-02-10
RU2020111042A (ru) 2021-09-17
MX2013003938A (es) 2013-07-05
JP5902698B2 (ja) 2016-04-13
AU2011315902A1 (en) 2013-05-30
RU2016134401A3 (hu) 2020-01-24
CA2813783A1 (en) 2012-04-19
CN103429245B (zh) 2016-10-05
AU2017200471B2 (en) 2018-04-12
US9492452B2 (en) 2016-11-15
EP2898885B1 (en) 2017-11-22
SI2898885T1 (en) 2018-03-30
KR101850925B1 (ko) 2018-04-20
RU2013121794A (ru) 2014-11-20
HK1257363A1 (zh) 2019-10-18
US20150051230A1 (en) 2015-02-19
RS56870B1 (sr) 2018-04-30
AU2017200471A1 (en) 2017-02-23
ES2536831T3 (es) 2015-05-29
HRP20180220T1 (hr) 2018-03-09
RS54072B1 (en) 2015-10-30
US11173159B2 (en) 2021-11-16
CA2813783C (en) 2019-01-22
ES2657687T3 (es) 2018-03-06
PL2627334T3 (pl) 2015-08-31
EP2627334A1 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
LT2898885T (lt) Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui
HRP20181497T1 (hr) Derivati purina za liječenje virusnih infekcija
HK1256490A1 (zh) 用於治療病毒感染的嘧啶衍生物
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
PL2903608T3 (pl) Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
ZA201306342B (en) The treatment of viral infections
ZA201308025B (en) The use of secnidazole in treating dental infections
GB201001821D0 (en) Treatment of viral infections